These shifts likely synergize with DIO’s direct anti-inflammatory properties, such as inhibition of NLRP3 inflammasome activation and downregulation of pro-inflammatory cytokines (e.g., TNF-α, IL-6), to disrupt the “gut-kidney axis” of inflammation in DN. The gene discussed is NLRP3; the disease is liver dysplastic nodule.